DexCom, Inc. (DXCM) earnings on July 30, 2026
Prior outlook: Optimistic Outcome: Accurate
DexCom stock jumped after the company released its earnings report. Analysts kept their positive view and raised their price targets for the stock.
DXCM price around the earnings
83.45
Change: +12.0%
2026-07-31, 20:00 UTC
Start of the measured window
End of the measured window
73.79
77.39
80.99
84.59
74.54
July 30, 2026
July 31, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Accurate
- Thesis published
- Results released
Strong buy with a 100% beat record and FDA TEMPO catalyst; price below support, high implied move 11%.
Context analyzed before publication
- Trend
- Strong positive trend strength and catalysts, but recent pullback and price significantly below support.
Analysts
Evidence
- Analyst consensus
- Strong buy
- Consensus average (1-5)
- 1.32
- Analysts covering the stock
- 25
- Average price target
- 86.16
- Lowest price target
- 65
- Highest price target
- 112
- Upside to price target
- 15.8%
- Quarterly earnings growth
- 89.3%
- Revenue growth
- 15%
- Forward EPS
- 3.08
- Trailing EPS
- 2.33
- Analyst moves in the last 60 days
- 7
- Strong buy: 3
- Buy: 22
- Hold: 3
- Sell: 0
- Strong sell: 0
- Strong buy
- 3
- Buy
- 22
- Hold
- 3
- Sell
- 0
- Strong sell
- 0
- July 16, 2026 · Truist Securities: Maintains rating (Buy → Buy)
- July 15, 2026 · Mizuho: Maintains rating (Outperform → Outperform)
- June 23, 2026 · Deutsche Bank: Initiates coverage (Buy → Buy)
- June 15, 2026 · Piper Sandler: Maintains rating (Overweight → Overweight)
- June 10, 2026 · TD Cowen: Maintains rating (Buy → Buy)
- June 9, 2026 · Mizuho: Maintains rating (Outperform → Outperform)
- June 5, 2026 · Stifel: Maintains rating (Buy → Buy)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (5)
- DexCom Selected As First Participant For FDA's TEMPO Digital Health Devices Program (opens in a new tab) — Benzinga
- Dexcom Selected By FDA As First Participant For Technology-Enabled Meaningful Patient Outcomes For Digital Health Devices Pilot (opens in a new tab) — Benzinga
- Truist Securities Maintains Buy on DexCom, Raises Price Target to $87 (opens in a new tab) — Benzinga
- Mizuho Maintains Outperform on DexCom, Raises Price Target to $90 (opens in a new tab) — Benzinga
- Dexcom Receives Health Canada Authorization For Dexcom G7 15 Day CGM System, Offering 15.5-Day Wear, 8.0% MARD Accuracy, And Fewer Sensor Changes For Canadians With Diabetes (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 75.17
- Average true range (ATR)
- 3.5%
- Distance to 52-week high
- -16.5%
- 14-day change (14d)
- +3.4%
- 30-day change (30d)
- +7.4%
- 30-day relative strength
- +16.0%
- QQQ change (30d)
- -8.6%
- Nearest support
- 74.59
- Distance to nearest support
- 0.8%
- Nearest resistance
- 75.47
- Distance to nearest resistance
- 0.4%
- Volume accumulation ratio (14d / 46d)
- 0.81
- Major: 74.59 (0.8% away, 0.22 ATR, 55 touches)
- Major: 73.96 (1.6% away, 0.46 ATR, 45 touches)
- Major: 73.53 (2.2% away, 0.62 ATR, 35 touches)
- Mid: 75.47 (0.4% away, 0.11 ATR, 11 touches)
- Major: 75.88 (0.9% away, 0.27 ATR, 40 touches)
- Major: 76.83 (2.2% away, 0.63 ATR, 34 touches)
Trends
Evidence
- Average earnings surprise
- +9.8%
- April 30, 2026: actual EPS 0.56 vs estimate 0.47 (surprise +19.0%)
- February 12, 2026: actual EPS 0.68 vs estimate 0.65 (surprise +4.5%)
- October 30, 2025: actual EPS 0.61 vs estimate 0.57 (surprise +7.5%)
- July 30, 2025: actual EPS 0.48 vs estimate 0.44 (surprise +8.3%)
Expected move
- Implied move
- +11.1%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 8.5%
- 75th percentile move
- 10.9%
- 90th percentile move
- 16.5%
- Up / down moves
- 10 / 10
- Average up move
- +9.7%
- Average down move
- -9.5%
Monitoring and close
What DexCom, Inc. reported
- Status
- Finished
| Actual EPS | 0.7 |
|---|---|
| EPS estimate | 0.61 |
| EPS surprise | +14.8% |
| Revenue | $1,308 million |
| Revenue estimate | $1,290 million |
| Revenue surprise | +1.4% |
DexCom beat Q2 expectations with record earnings and revenue, and raised its 2026 sales guidance, reflecting optimism.
Sources (8)
- DexCom Q2 Earnings Call Highlights (opens in a new tab) — MarketBeat
- DexCom (DXCM) Q2 Earnings and Revenues Top Estimates (opens in a new tab) — Zacks
- Dexcom (NASDAQ:DXCM) Beats Q2 Earnings Estimates, Raises Profitability Guidance (opens in a new tab) — ChartMill
- DexCom’s (NASDAQ:DXCM) Q2 CY2026 Sales Beat Estimates (opens in a new tab) — StockStory
- DexCom Raises FY2026 Sales Guidance from $5.160B-$5.250B to $5.180B-$5.250B vs $5.224B Est (opens in a new tab) — Benzinga
- DexCom reported adjusted EPS of $0.70, beating the $0.61 estimate, and revenue of $1.308B, above the $1.290B expected. — Benzinga
- DexCom Q2 Adj. EPS $0.70 Beats $0.61 Estimate, Sales $1.308B Beat $1.290B Estimate (opens in a new tab) — Benzinga
- Dexcom Reports Second Quarter 2026 Financial Results (opens in a new tab) — Yahoo
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, results beat expectations on both earnings and revenue, and the price is indicating +7.3% pre-market, a move in line with the stock's usual reaction (about 8%). The figures confirm the optimistic scenario. Across our market history, in the 1,431 similar cases the close held that direction 96% of the time.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- +11.9%
- Max favorable move (MFE)
- 13.6%
- Max adverse move (MAE)
- 1.3%